DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+42.82%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$417M
AUM Growth
+$417M
(+30%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-3.54%
Top 10 Holdings %
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$6.14M |
| 2 |
Biohaven
BHVN
|
$5.73M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$3.28M |
| 5 |
Galapagos
GLPG
|
$2.85M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$7.23M |
| 3 |
Cytokinetics
CYTK
|
$6.64M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$4.75M |
| 5 |
Nurix Therapeutics
NRIX
|
$4.38M |
Sector Composition
| 1 | Healthcare | 85.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.25M | 1.26% |
89,387
-3,500
| -4% | -$206K |
|
27
Edgewise Therapeutics
EWTX
$1.54B
| $4.92M | 1.18% |
449,384
-70,000
| -13% | -$766K |
|
28
Alector
ALEC
$282M
| $4.87M | 1.17% |
609,905
-19,033
| -3% | -$152K |
|
29
Viking Therapeutics
VKTX
$3.02B
| $4.62M | 1.11% |
248,217
-71,438
| -22% | -$1.33M |
|
30
AtriCure
ATRC
$1.73B
| $4.48M | 1.07% |
125,529
| – | – |
|
31
Arcus Biosciences
RCUS
$1.24B
| $4.44M | 1.07% |
232,717
+10,000
| +4% | +$191K |
|
32
Century Therapeutics
IPSC
$40.4M
| $4.34M | 1.04% |
1,307,407
| – | – |
|
33
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.25M | 1.02% |
709,500
+57,500
| +9% | +$344K |
|
34
Accuray
ARAY
$165M
| $3.46M | 0.83% |
1,222,358
| – | – |
|
35
Astria Therapeutics
ATXS
$394M
| $3.45M | 0.83% |
449,008
+153,515
| +52% | +$1.18M |
|
36
Keros Therapeutics
KROS
$640M
| $2.96M | 0.71% |
74,361
+8,400
| +13% | +$334K |
|
|
SLRN
37
DELISTED
ACELYRIN
SLRN
| $2.77M | 0.66% |
371,200
+363,900
| +4,985% | +$2.71M |
|
38
Procept Biorobotics
PRCT
$2.11B
| $2.65M | 0.64% |
63,300
-4,000
| -6% | -$168K |
|
39
MediWound
MDWD
$180M
| $2.62M | 0.63% |
257,653
| – | – |
|
|
BCYC
40
Bicycle Therapeutics
BCYC
$492M
| $2.21M | 0.53% |
122,200
| – | – |
|
|
BWAY
41
Brainsway
BWAY
$296M
| $2M | 0.48% |
308,471
-123,710
| -29% | -$802K |
|
42
ProQR Therapeutics
PRQR
$256M
| $1.86M | 0.45% |
940,582
| – | – |
|
43
Amylyx Pharmaceuticals
AMLX
$877M
| $1.8M | 0.43% |
122,547
| – | – |
|
|
MREO
44
Mereo BioPharma
MREO
$275M
| $1.8M | 0.43% |
778,813
-183,700
| -19% | -$424K |
|
45
Immunovant
IMVT
$2.91B
| $1.72M | 0.41% |
40,742
+18,242
| +81% | +$769K |
|
46
ARS Pharmaceuticals
SPRY
$1.08B
| $1.71M | 0.41% |
+311,169
| New | +$1.71M |
|
|
CMPS
47
Compass Pathways
CMPS
$452M
| $1.69M | 0.4% |
193,000
| – | – |
|
|
SYRS
48
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.67M | 0.4% |
214,885
-50,993
| -19% | -$397K |
|
|
SPRB
49
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $1.61M | 0.39% |
548,510
-21,620
| -4% | -$63.3K |
|
50
Larimar Therapeutics
LRMR
$337M
| $1.47M | 0.35% |
323,873
-3,500
| -1% | -$15.9K |
|